Treating severe acne. It may also be used for other conditions as determined by your doctor.
Derma T lotion is a topical lincomycin antibiotic. It works by killing sensitive bacteria that cause acne and reducing the amount of free fatty acids that irritate the skin surface.
Derma T indications
An indication is a term used for the list of condition or symptom or illness for which the medicine is prescribed or used by the patient. For example, acetaminophen or paracetamol is used for fever by the patient, or the doctor prescribes it for a headache or body pains. Now fever, headache and body pains are the indications of paracetamol. A patient should be aware of the indications of medications used for common conditions because they can be taken over the counter in the pharmacy meaning without prescription by the Physician.
sponsored
Derma T Injection, USP is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria.
Derma T Injection, USP is also indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci, and staphylococci. Its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. Because of the risk of antibiotic-associated pseudomembranous colitis, as described in the WARNING box, before selecting Derma T the physician should considere the nature of the infection and the suitability of less toxic alternatives (e.g., erythromycin).
Bacteriologic studies should be performed to determine the causative organisms and their susceptibility to Derma T.
Indicated surgical procedures should be performed in conjunction with antibiotic therapy.
Derma T Injection, USP is indicated in the treatment of serious infections caused by susceptible strains of the designated organisms in the conditions listed below:
Lower respiratory tract infections including pneumonia, empyema, and lung abscess caused by anaerobes, Streptococcus pneumoniae, other streptococci (except E. faecalis), and Staphylococcus aureus.
Skin and skin structure infections caused by Streptococcus pyogenes, Staphylococcus aureus, and anaerobes.
Gynecological infections including endometritis, nongonococcal tubo-ovarian abscess, pelvic cellulitis, and postsurgical vaginal cuff infection caused by susceptible anaerobes.
Intra-abdominal infections including acute hematogenous osteomyelitis caused by Staphylococcus aureus and as adjunctive therapy in the surgical treatment of chronic bone and joint infections due to susceptible organisms.
Septicemia caused by Staphylococcus aureus, streptococci (except Enterococcus faecalis), and susceptible anaerobes.
Bone and joint infections including acute hematogenous osteomyelitis caused by Staphylococcus aureus and as adjunctive therapy in the surgical treatment of chronic bone and joint infections due to susceptible organisms.
To reduce the development of drug-resistant bacteria and maintain the effectiveness of Derma T and other antibacterial drugs, Derma T should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.
How should I use Derma T?
Use Derma T as directed by your doctor. Check the label on the medicine for exact dosing instructions.
An extra patient leaflet is available with Derma T. Talk to your pharmacist if you have questions about this information.
Derma T is for topical use on the skin only.
Wash the affected areas to be treated with mild soap and water and allow the skin to dry thoroughly.
To use Derma T, hold the can upright and dispense the amount of medicine to be used directly into the cap or onto a cool surface. Pick up small amounts of the foam with your fingertips and gently massage it into the affected areas until the foam disappears.
If the can seems warm or the foam seems runny, hold the can under cold running water to cool it. Do not dispense the medicine directly onto your skin or hands because it will melt too soon.
Throw away any unused medicine that has been dispensed out of the can.
Wash your hands immediately after using Derma T.
Use Derma T on a regular schedule to get the most benefit from it.
If you miss a dose of Derma T, use it as soon as possible. If it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule. Do not use 2 doses at once.
Ask your health care provider any questions you may have about how to use Derma T.
Uses of Derma T in details
There are specific as well as general uses of a drug or medicine. A medicine can be used to prevent a disease, treat a disease over a period or cure a disease. It can also be used to treat the particular symptom of the disease. The drug use depends on the form the patient takes it. It may be more useful in injection form or sometimes in tablet form. The drug can be used for a single troubling symptom or a life-threatening condition. While some medications can be stopped after few days, some drugs need to be continued for prolonged period to get the benefit from it.
sponsored
This medication is used to treat acne. It helps to decrease the number of acne lesions. Derma T is an antibiotic which works by stopping the growth of bacteria.
How to use Derma T topical
Use this medication only on the skin. Clean and dry the affected area first. Follow all directions on the product package, or use as directed by your doctor.
If you are using the lotion, shake the bottle well before using. Apply a thin layer of medication usually twice a day or as directed by your doctor.
If you are using the medicated pad or swab, apply to the the affected area gently with it, then discard. Depending on the size of the area to be treated, more than one pad or swab may be necessary.
If you are using the foam, apply it once daily to the affected areas. Use enough to cover the entire affected area. Do not spray the foam directly onto your hands or face, because the foam will begin to melt on contact with warm skin. Instead spray the amount needed directly into the cap or onto a cool surface such as a counter top. If the can seems warm or the foam seems runny, run the can under cold water. Please read the patient information leaflet available from your pharmacist for specific instructions on how to use the foam, and ask about any information that is unclear.
Wash your hands after use.
Avoid contact with your eyes, nose, mouth or any areas of broken skin. If you accidentally get medication in these areas, rinse well with plenty of cool water.
It may take between 2-6 weeks to notice an improvement in your condition, and up to 12 weeks to see the full benefit.
Inform your doctor if your condition does not improve or worsens.
Derma T description
sponsored
Each mL of Dalacin T
Topical Solution contains Clindamycin Phosphate 10 mg. Dalacin T
Topical Solution also contains the following excipients: Isopropyl alcohol, propylene glycol, hydrochloric acid, sodium hydroxide and water.
Each mL of Dalacin T
Topical Lotion contains Clindamycin Phosphate 10 mg. Dalacin T
Topical Lotion also contains the following excipients: Glycerol, sodium lauroyl sarcosinate, stearic acid, glyceryl stearate SE (with potassium monostearate), cetostearyl alcohol, isostearyl alcohol, methylparaben and water.
Each topical gel contains Clindamycin Phosphate at a concentration equivalent to Derma T 10 mg/g. Dalacin T
Topical Gel also contains the following excipients: Allantoin, carbomer 934P, methylparaben, polyethylene glycol 400, propylene glycol, sodium hydroxide and purified water.
Derma T is a water-soluble ester of the semi-synthetic antibiotic produced by a 7(S)-chloro-substitution of the 7(R)-hydroxyl group of the parent antibiotic, lincomycin.
The chemical name for Derma T is 7(S)-chloro-7-deoxylincomycin-2-phosphate. It has a molecular formula of C18H34ClN2O8PS and a molecular weight of 504.96.
Derma T dosage
sponsored
Apply a thin film of Derma T
Topical Solution twice daily to affected area. Keep all liquid dosage forms in containers tightly closed.
How supplied
Derma T
Topical Solution, USP 1%
containing Derma T equivalent to 10 mg Derma T per milliliter is available in the following sizes:
30 mL applicator bottles - NDC 0472-0987-91
60 mL applicator bottles - NDC 0472-0987-92
Store at 20°-25°C (68°-77°F). Protect from freezing.
Inform the physician or pharmacist if the patient is taking or has recently taken other medication (ie, with/without prescription). The solution and lotion of Dalacin T should not be used concomitantly with any skin treatment containing benzoyl peroxide.
Derma T has been shown to have neuromuscular blocking properties that may enhance the action of other neuromuscular blocking agents. Therefore, it should be used with caution in patients receiving such agents.
Warfarin or similar medicines-used to thin the blood. The patient may be more likely to have a bleed. The physician may need to take regular blood tests to check how well the blood can clot.
In clinical trials involving non-pregnant women, 1.8% of 600 patients who received treatment with Derma T vaginal cream 2% for 3 days and 2.7% of 1325 patients who received treatment for 7 days discontinued therapy due to drug-related adverse events. Medical events judged to be related, probably related, possibly related, or of unknown relationship to vaginally administered Derma T vaginal cream 2%, were reported for 20.7% of the patients receiving treatment for 3 days and 21.3% of the patients receiving treatment for 7 days. Events occurring in ≥1% of patients receiving Derma T vaginal cream 2% are shown in Table 1.
TABLE 1 – Events Occurring in ≥1% of Non-pregnant Patients Receiving Derma T Vaginal Cream 2%
Derma T Vaginal Cream
Event
3 Day
n=600
7 Day
n=1325
Urogenital
Vaginal moniliasis
7.7
10.4
Vulvovaginitis
6.0
4.4
Vulvovaginal disorder
3.2
5.3
Trichomonal vaginitis
0
1.3
Body as a Whole
Moniliasis (body)
1.3
0.2
Other events occurring in <1% of the Derma T Vaginal Cream 2% groups include:
In a clinical trial involving pregnant women during the second trimester, 1.7% of 180 patients who received treatment for 7 days discontinued therapy due to drug-related adverse events. Medical events judged to be related, probably related, possibly related, or of unknown relationship to vaginally administered Derma T vaginal cream 2%, were reported for 22.8% of pregnant patients. Events occurring in ≥1% of patients receiving either Derma T vaginal cream 2% or placebo are shown in Table 2.
TABLE 2 - Events Occurring in ≥1% of Pregnant Patients Receiving Derma T Vaginal Cream 2% or Placebo
Derma T Vaginal Cream
Placebo
Event
7 DAY
n=180
7 DAY
n=184
Urogenital
Vaginal moniliasis
13.3
7.1
Vulvovaginal disorder
6.7
7.1
Abnormal labor
1.1
0.5
Body as a Whole
Fungal infection
1.7
0
Skin
Pruritus, non-application site
1.1
0
Other events occurring in <1% of the Derma T Vaginal Cream 2% group include:
Urogenital system: dysuria, metrorrhagia, vaginal pain, and trichomonal vaginitis.
Body as a whole: upper respiratory infection.
Skin: pruritus (topical application site) and erythema.
Post-marketing Experience
Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
In the post-marketing period, there have been case reports of pseudomembranous colitis with the use of Derma T vaginal cream.
Other Derma T formulations
Derma T Vaginal Cream affords minimal peak serum levels and systemic exposure (AUCs) of Derma T compared to 100 mg oral Derma T dosing. Although these lower levels of exposure are less likely to produce the common reactions seen with oral Derma T, the possibility of these and other reactions cannot be excluded presently. Data from well-controlled trials directly comparing Derma T administered orally to Derma T administered vaginally are not available.
The following adverse reactions and altered laboratory tests have been reported with the oral or parenteral use of Derma T:
Gastrointestinal: Abdominal pain, esophagitis, nausea, vomiting, diarrhea and pseudomembranous colitis.
Hematopoietic: Transient neutropenia (leukopenia), eosinophilia, agranulocytosis, and thrombocytopenia have been reported. No direct etiologic relationship to concurrent Derma T therapy could be made in any of these reports.
Hypersensitivity Reactions: Maculopapular rash and urticaria have been observed during drug therapy. Generalized mild to moderate morbilliform-like skin rashes are the most frequently reported of all adverse reactions. Rare instances of erythema multiforme, some resembling Stevens-Johnson syndrome, have been associated with Derma T. A few cases of anaphylactoid reactions have been reported. If a hypersensitivity reaction occurs, the drug should be discontinued.
Liver: Jaundice and abnormalities in liver function tests have been observed during Derma T therapy.
Musculoskeletal: Rare instances of polyarthritis have been reported.
Renal: Although no direct relationship of Derma T to renal damage has been established, renal dysfunction as evidenced by azotemia, oliguria, and/or proteinuria has been observed in rare instances.
Derma T topical solution, Derma T topical gel and Derma T topical lotion are contraindicated in individuals with a history of hypersensitivity to preparations containing Derma T or lincomycin, a history of regional enteritis or ulcerative colitis, or a history of antibiotic-associated colitis.
The results of a survey conducted on ndrugs.com for Derma T are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Derma T. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.
User reports
Consumer reported useful
No survey data has been collected yet
Consumer reported price estimates
No survey data has been collected yet
Consumer reported time for results
No survey data has been collected yet
Consumer reported age
No survey data has been collected yet
Consumer reviews
There are no reviews yet. Be the first to write one!